

### AMENDMENTS TO THE CLAIMS

#### Claims 1-7 (Withdrawn)

8. (Currently Amended) A ~~non-human~~ transgenic ~~animal~~ mouse whose genome comprises a homozygous ~~comprising~~ a disruption in a cerberus gene nucleotide sequence set forth in SEQ ID NO: 1, wherein the disruption comprises a disruption of the nucleotide sequence set forth in SEQ ID NO: 1, and wherein said transgenic mouse exhibits, relative to a wild-type mouse, a phenotype selected from the group consisting of a decrease in average velocity of movement during open field testing, a decrease in total distance traveled during open field testing, an increase in the number of fecal boli during open field testing, and a decrease in total time immobile during the tail suspension test.

#### Claim 9 (Withdrawn)

10. (Currently Amended) A method of producing a transgenic mouse comprising a homozygous disruption in a cerberus gene set forth in SEQ ID NO: 1, the method comprising:
- (a) introducing the ~~targeting construct of claim 1 into a cell~~ a construct that targets the nucleotide sequence set forth in SEQ ID NO: 1 into a mouse embryonic stem cell;
  - (b) introducing the embryonic stem cell into a blastocyst;
  - (c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and
  - (d) breeding the chimeric mouse to produce the transgenic mouse comprising a disruption in the cerberus gene, wherein the transgenic mouse when homozygous for the disruption exhibits, relative to a wild-type mouse, a phenotype selected from the group consisting of a decrease in average velocity of movement during open field testing, a decrease in total distance traveled during open field testing, an increase in the number of fecal boli during open

Application No. 09/887,552  
Deltagen Docket No. R-67

field testing, and a decrease in total time immobile during the tail suspension  
test.

Claims 11-16 (Withdrawn)